In this study we will see effects of melatonin tablets on S100B protein in delirium patients
Phase 1
Completed
- Conditions
- Health Condition 1: F05- Delirium due to known physiological condition
- Registration Number
- CTRI/2019/12/022200
- Lead Sponsor
- King Georges Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 73
Inclusion Criteria
1. Diagnosis of Delirium qualifying according to ICD-10 (international classification of disease-10).
2. Age 60-95 years
3. Patientâ??s family members willing to give consent.
Exclusion Criteria
1. Past history of seizure, ischemic or haemorrhagic CVA or traumatic brain injury and encephalitis.
2. IQCODE score >= 3.5 to exclude dementia.
3. Unreliable informants.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method S100B is a calcium binding protein which increases in delirium. Melatonin is a important neurotransmitter which is essential for sleep induction. The hypothesis that melatonin decreases the S100B protein and might be useful for the treatment of delirium.Timepoint: SEVEN DAYS
- Secondary Outcome Measures
Name Time Method 1.To study the severity of delirium before and after giving exogenous melatonin. <br/ ><br>2.To study the relation between S100B protein level and the severity of delirium. <br/ ><br>Timepoint: SEVEN DAYS